Bone cancer pain

Jiménez-Andrade, Juan Miguel; Mantyh, William G.; Bloom, Aaron P.; Ferng, Alice S.; Geffre, Christopher P.; Mantyh, Patrick W.

doi:10.1111/j.1749-6632.2009.05429.x

Cited by 230 publications

(180 citation statements)

References 29 publications

Supporting

Mentioning

176

Contrasting

Unclassified

Order By: Relevance

“…As these two cancer types are among the cancers most frequently giving rise to bone metastases [121], and as bone metastases are acknowledged to be an important cause of cancer BTP, research into the mechanisms of metastatic bone pain due to breast cancer and lung cancer seems to be an important area for future studies [119]. This would entail biomarker studies in human, in analogy with the biomarker studies for neuropathic pain described in Papers III and IV.…”

Section: Improving the Treatment Of Cancer Breakthrough Painmentioning

confidence: 99%

The Cerebrospinal Fluid in Severe Pain Conditions : Clinical, Pharmacological and Proteomic Aspects

Bäckryd¹

2015

View full text Add to dashboard Cite

The treatment of both cancer pain and non-cancer chronic pain is still suboptimal. The overall aim of this PhD thesis was to conduct translational pain research at the interface between clinical pain medicine and the field of human proteomics, using the practice of intrathecal analgesia at our institution as a starting point. Hence, the cerebrospinal fluid (CSF) is at the centre of the present dissertation, both as a target for infusing analgesics (Papers I and II – clinical and pharmacological aspects) and as an important biofluid for human biomarker studies (Papers III and IV – proteomic aspects). In Paper I, 28 cases of intrathecal analgesia in cancer patients were prospectively followed. Movement-evoked breakthrough pain remained a major clinical problem throughout the study month despite otherwise successful intrathecal analgesia (defined as good control of spontaneous resting pain paralleled by a marked decrease of concomitant systemic opioid doses). This study therefore illustrates the importance of considering not only spontaneous resting pain but also movement-evoked breakthrough pain. In Paper II, an expert-based algorithm for trialing the intrathecal analgesic ziconotide by bolus injections was evaluated in an open-label study of 23 patients with chronic neuropathic pain. We found few responders (13%) according to the strict criteria of the algorithm, but ziconotide bolus injection trialing seems feasible. The predictive power of ziconotide bolus trialing remains unclear, and the pharmacological profile of ziconotide (with very slow tissue penetration due to high hydrophilicity) calls the rationale for ziconotide bolus trialing into question. In Paper III, we found low levels of beta-endorphin in the CSF of chronic neuropathic pain patients (n=15) compared to healthy controls (n=19). We speculate that this might indicate dysfunctional top-down control of nociception. Substance P levels in the CSF did not differ by univariate statistics. In Paper IV, the CSF proteome of 11 patients with chronic neuropathic pain and 11 healthy controls was exploratively studied, combining gel-based proteomics with multivariate data analysis. After eliminating four proteins associated with age, 32 proteins were found to highly discriminate between groups. Among these, the seven proteins having the highest discriminatory power between patients and controls were: one isoform of angiotensinogen, two isoforms of alpha-1-antitrypsin, three isoforms of haptoglobin, and one isoform of pigment epithelium-derived factor. In conclusion, this PhD thesis demonstrates the fruitfulness of studying the CSF, both as a target for infusing analgesics and as a potential mirror of the neurobiological processes involved in pathological pain conditions. The thesis points to the need for more research into the mechanisms of different pain conditions, in order to hopefully achieve the vision of mechanism-based pain diagnoses

show abstract

Section: Improving the Treatment Of Cancer Breakthrough Painmentioning

confidence: 99%

The Cerebrospinal Fluid in Severe Pain Conditions : Clinical, Pharmacological and Proteomic Aspects

Bäckryd¹

2015

View full text Add to dashboard Cite

show abstract

“…23 Particularly, bone is the only site of metastasis for prostate cancer, whereas approximately 70% of metastatic breast cancers metastasize to bone. 23,24 Therefore, the treatment of metastasized cancers in bone (termed "cancer bone metastasis" hereafter) is important for patients in providing prolonged survival rates; it has also recently emerged as an important bone disease to target. As described by Coleman, 25 the skeleton is the most common organ to be affected by metastatic cancer, and this is the site of the disease that produces the greatest morbidity rates.…”

Section: Targeted Delivery For Preventing and Treating Cancer Bone Mementioning

confidence: 99%

Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration

Wu²,

Chen³

et al. 2013

IJN

166

111

View full text Add to dashboard Cite

Nanotechnology is a vigorous research area and one of its important applications is in biomedical sciences. Among biomedical applications, targeted drug delivery is one of the most extensively studied subjects. Nanostructured particles and scaffolds have been widely studied for increasing treatment efficacy and specificity of present treatment approaches. Similarly, this technique has been used for treating bone diseases including bone regeneration. In this review, we have summarized and highlighted the recent advancement of nanostructured particles and scaffolds for the treatment of cancer bone metastasis, osteosarcoma, bone infections and inflammatory diseases, osteoarthritis, as well as for bone regeneration. Nanoparticles used to deliver deoxyribonucleic acid and ribonucleic acid molecules to specific bone sites for gene therapies are also included. The investigation of the implications of nanoparticles in bone diseases have just begun, and has already shown some promising potential. Further studies have to be conducted, aimed specifically at assessing targeted delivery and bioactive scaffolds to further improve their efficacy before they can be used clinically.

show abstract

“…Bone cancer pain is a high-risk of malignancies in patients with breast, prostate and lung cancer as these tumors have a remarkable ability to metastasize to bone (78).…”

Section: Involvement Of Ngf and Trka In Cancer Painmentioning

confidence: 99%

The role of nerve growth factor and its receptors in tumorigenesis and cancer pain

Wang

Chen

Guo

2014

BST

View full text Add to dashboard Cite

Bone cancer pain

Cited by 230 publications

References 29 publications

The Cerebrospinal Fluid in Severe Pain Conditions : Clinical, Pharmacological and Proteomic Aspects

The Cerebrospinal Fluid in Severe Pain Conditions : Clinical, Pharmacological and Proteomic Aspects

Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration

The role of nerve growth factor and its receptors in tumorigenesis and cancer pain

Contact Info

Product

Resources

About